Differentiation antigens in tumors: Dependence on carcinogenesis mechanisms and progression (a hypothesis)

Molekulyarnaya Biologiya

Volumn 37, Issue 1, 2003, Pages 4-11

  Abelev, G I ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULE; DIFFERENTIATION ANTIGEN; FETAL ANTIGEN; INTEGRIN; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; TUMOR MARKER;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL INTERACTION; CELL TRANSFORMATION; ENZYME RELEASE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; HYPOTHESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVIEW; TUMOR; TUMOR GROWTH; EMBRYO; EPITHELIUM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ALPHA-FETOPROTEINS; ANTIGENS, DIFFERENTIATION; CARCINOEMBRYONIC ANTIGEN; CELL TRANSFORMATION, NEOPLASTIC; EMBRYO; EPITHELIUM; GENE EXPRESSION REGULATION; NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0038343454     PISSN: 00268984     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Stevenson G.T., Cragg M.S. 1999. Molecular markers of B-cell limphoma. Semin. Cancer Biol. 9, 199-147.
2. Abelev G.I. 1965. Antigenic structure of chemically induced hepatomas. Progr. Exp. Tumor Res. 7, 104-157.
3. Schreiber H. 1994. Tumor Immunology. In: Fundamental Immunology (3rd edition). Ed. Paul W. N.Y: Raven Press, pp. 1143-1178.
4. Boon T., Cerrotini J.-C., Van den Eyude B., Van den Bruggen P., Van Pel L. 1994. Tumor antigens recognized by T-lymphocytes. Ann. Rev. Immunol. 12, 337-366.
5. Berenblum I. 1954. A speculative review: the probable nature of promoting action and its significance in the understanding of the mechanism of carcinogenesis. Cancer Res. 14, 471-477.
6. Hahn W.C., Weinberg R. 2002. Modelling the molecular circuits of cancer. Nature Reviews Cancer. 2, 331-341.
7. Nowell P.C. 2002. Tumor progression: a brief historical perspective. Semin. Cancer Biol. 12, 261-266.
8. Hanahan D., Weinberg R.A. 2000. The hallmarks of cancer. Cell. 100, 57-70.
9. Krutovskikh V. 2002. Implication of direct host-tumor intercellular interactions in non-immune host resistance to neoplastic growth. Semin. Cancer Biol. 12, 267-276.
10. Laconi S., Pani P., Pillai S., Pasciu D., Sarma D.S.R., Laconi E. 2001. A growth-constrained environment drives tumor progression in vivo. Proc. Natl. Acad. Sci. USA. 98, 7807-7811.
11. Bauer G. 1996. Elimination of transformed cells by normal cells: a novel concept for the control of carcinogenesis. Histol. Histopathol. 11, 237-255.
12. Laconi E., Oren R., Mukhopadhyay D.K., Hurston E., Laconi S., Pani P., Dabeva M.D., Shafritz D.A. 1998. Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retrorsine. Am. J. Pathol. 153, 319-329.
13. McCullough K.D., Coleman W.B., Ricketts S.L., Wilson J.W., Smith G.I., Grisham J.W. 1998. Plasticity of the neoplastic phenotype in vivo is regulated by epigenetic factors. Proc. Natl. Acad. Sci. USA. 95, 15333-15338.
14. Mintz B., Illmensee K. 1975. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. USA. 72, 3585-3589.
15. Korsmeyer S.J. 1992. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu. Rev. Immunol. 10, 785-807.
16. Tenen D.G., Hromas R., Licht J.D., Zhang D.E. 1997. Transcription factors, normal myeloid development, and leukemia. Blood. 90, 489-519.
17. Yoshida M., Seiki M. 1987. Recent advances in the molecular biology of HTLV-1: trans-activation of viral and cellular genes. Annu. Rev. Immunol. 5, 541-559.
18. Rabbitts T.H. 1998. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes Dev. 12, 2651-2657.
19. Zaret K.S. 2002. Regulatiry phases of early liver development: paradigms of organogenesis. Nature Reviews. 3, 499-512.
20. Matsumoto K., Yoshitomi H., Rossant J., Zaret K.S. 2001. Liver organogenesis promoted by endothelial cells prior to vascular function. Science. 249, 559-563.
21. Bhatia S.N., Balis U.J., Yarmush M.L., Toner M. 1999. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB. 13, 1883-1900.
22. Michalopoulos O.K., Bowen W.C., Zajac V.F., Beer-Stols D., Watkins S., Kostrubsky V., Strom S.C. 1999. Morphogenetic events in mixed cultures of rat hepatocytes and nonparenchymal cells maintained in biological matrices in the presence of hepatocyte growth factor and epidermal growth factor. Hepatology. 29, 90-100.
23. Guguen-Guillouzo C, Clement B., Baffet G., Beammont C., Morel-Chany E., Glaise D., Guillouzo A. 1983. Maintenance and reversibility of active albumin secretion by adult rat hepatocytes co-cultured with another liver epithelial cell type. Exp. Cell Res. 143, 47-54.
24. Guillouzo A., Morel F., Fardel O., Meunier B. 1993. Use of human hepatocyte cultures for drug metabolism studies. Toxicology. 82, 209-219.
25. Gleiberman A., Abelev G. 1985. Cell position and cell interactions in expression of fetal phenotype of hepatocyte. Intern. Rev. Cytology. 95, 229-266.
26. Yeaman C., Grindstaff K.K., Nelson W.J., 1999. New perspectives on mechanisms involved in generating epithelial cell polarity. Physiol Rev. 79, 73-98.
27. Lin C.Q., Bissell M.J. 1993. Multi-faceted regulation of cell differentiation by extracellular matrix. FASEB. 7, 737-743.
28. Cukierman E., Pankov R., Stevens D.R., Yamada K.M. 2001. Taking cell-matrix adhesions to the third dimension. Science. 294, 1708-1712.
29. Weaver V.M., Petersen O.W., Wang F., Larabell C.A., Briand P., Damsky C., Bissell M.J. 1997. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell. Biol. 137(1), 231-245.
30. Bauer G. 1995. Resistance to TGF-β-induced elimination of transformed cells is required during tumor progression (review-hypothesis). Intern. J. Oncol. 6, 1227-1229.
31. Deichman G.I. (ed). 2002. Innate host antitumour immunity and tumor progression. Semin. Cancer Biol. 12 (4).
32. Deichman G.I. 2002. Early phenotypic changes of in vitro transformed cells during in vivo progression: possible role of the host innate immunity. Semin. Cancer. Biol. 12, 317-320.
33. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. 1988. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532.
34. Rudisky D., Hagios C., Bissel M. 2000. Tumors are unique organs defined by abnormal signaling and contact. Semin. Cancer Biol. 11, 87-95.
35. Howe A., Aplin A., Alahari S., Juliano R. 1998. Integrin signaling and cell growth control. Curr. Opin. Cell. Biol. 10, 220-231.
36. Goodman S., Mark K. (eds). 1996. Extracellular matrix and integrins. Semin. Cancer Biol. 7(1).
37. Callahan R., Salomon D. 1993. Oncogenes tumour suppressor genes and growth factors in breast cancer: Novel largest for diagnosis, prognosis and therapy. Cancer Surveys. 18, 35-56.
38. Chuny L., Cleave M., Hsich J.-T., Hong S.-J., Zan H. 1991. Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Cancer Surveys. 11, 91-121.
39. Stetler-Stevenson W., Yu A.E. 2001. Proteases in invasion: matrix metalloproteinases. Semin. Cancer Biol. 11, 143-152.
40. Abelev G.I. & Eraizer T.L. 1999. Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin. Cancer Biology. 9, 95-104.
41. Kudrjavtseva E.I. 1997. Extracellular matrix is important factor for tissue-specitic hepatocyte organization. Eur. J. Cell Biol. 74, supplement, p. 47.
42. Abelev G.I., Sell S. 1999. Introduction. Semin. in Cancer Biology. Tumor Markers. 9, (2), 61-66.
43. Hammerstrom S. 1999. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67-82.
44. Stenman U.-H., Leinonen J., Zhang W.-M., Finne P. 1999. Prostate-specific antigen. Semin. Cancer Biol. 9, 83-94.
45. Ross Y.S., Fletcher J. 1999. The Her 2/new oncogene: prognostic factor, predictive factor and target for therapy. Semin. Cancer Biol. 9, 125-138.
46. Dipersio C., Yackson D., Zaret K. 1991. The extracellular matrix coordinately modulates liver transcryption factors and hepatocyte morphology. Mol. Cell. Biol. 11, 4495-4514.